Tyler Stone Wealth Management Boosts Holdings in Johnson & Johnson (NYSE:JNJ)

Tyler Stone Wealth Management lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,500 shares of the company’s stock after purchasing an additional 192 shares during the period. Tyler Stone Wealth Management’s holdings in Johnson & Johnson were worth $940,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund acquired a new stake in Johnson & Johnson during the fourth quarter worth $362,000. Aviso Wealth Management boosted its stake in Johnson & Johnson by 35.1% during the fourth quarter. Aviso Wealth Management now owns 15,719 shares of the company’s stock worth $2,273,000 after buying an additional 4,081 shares during the period. Heritage Wealth Advisors increased its position in shares of Johnson & Johnson by 5.1% during the fourth quarter. Heritage Wealth Advisors now owns 326,628 shares of the company’s stock valued at $47,237,000 after acquiring an additional 15,778 shares during the last quarter. Graney & King LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter worth approximately $241,000. Finally, Borer Denton & Associates Inc. increased its holdings in Johnson & Johnson by 0.6% in the 4th quarter. Borer Denton & Associates Inc. now owns 64,035 shares of the company’s stock valued at $9,261,000 after purchasing an additional 355 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on JNJ. Barclays upped their price target on Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Tuesday, January 28th. Bank of America raised their target price on Johnson & Johnson from $159.00 to $171.00 and gave the company a “neutral” rating in a report on Wednesday, March 5th. Royal Bank of Canada reiterated an “outperform” rating and set a $181.00 price target on shares of Johnson & Johnson in a research note on Wednesday, February 19th. Argus upgraded shares of Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Finally, Stifel Nicolaus reduced their target price on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a report on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus price target of $171.33.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $161.14 on Wednesday. The stock has a market cap of $388.32 billion, a PE ratio of 24.23, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The firm’s fifty day simple moving average is $157.70 and its 200-day simple moving average is $156.14. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. Johnson & Johnson’s revenue was up 5.3% on a year-over-year basis. During the same period in the previous year, the firm posted $2.29 earnings per share. Analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.08%. The ex-dividend date was Tuesday, February 18th. Johnson & Johnson’s payout ratio is currently 74.59%.

Insiders Place Their Bets

In related news, VP Robert J. Decker sold 6,999 shares of the stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares of the company’s stock, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at $2,357,552.70. The trade was a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.